Noureddin, Mazen

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Danpanichkul, P., Díaz, L. A., Suparan, K., Tothanarungroj, P., Sirimangklanurak, S., Auttapracha, T., Blaney, H. L., Sukphutanan, B., Pang, Y., Kongarin, S., et al. (2025) · Clinical and Molecular Hepatology

Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

Cited by 85

Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis

Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 83

Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis

Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 69

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 63

Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD - an umbrella overview of systematic review of meta-analysis

Xiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 56

Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma

Zeng, R. W., Ong, C. E. Y., Ong, E. Y. H., Chung, C. H., Lim, W. H., Xiao, J., Danpanichkul, P., Law, J. H., Syn, N., Chee, D., et al. (2024) · Clinical Gastroenterology and Hepatology

Hepatocellular Carcinoma Treatment and PrognosisAlcohol Consumption and Health Effects

Cited by 47

Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis

Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology

Liver Disease Diagnosis and TreatmentGalectins and Cancer Biology

Cited by 47

Insulin Signaling as a Potential Natural Killer Cell Checkpoint in Fatty Liver Disease

Amer, J., Salhab, A., Noureddin, M., Doron, S., Abu‐Tair, L., Ghantous, R., Mahamid, M., & Safadi, R. (2018) · Hepatology Communications

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 42

Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly

Danpanichkul, P., Suparan, K., Ng, C. H., Dejvajara, D., Kongarin, S., Panpradist, N., Chaiyakunapruk, N., Muthiah, M. D., Chen, V. L., Huang, D. Q., et al. (2024) · JHEP Reports

Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

Cited by 37

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

Aboona, M. B., Danpanichkul, P., Chen, V. L., Rangan, P., Kim, D., Alkhouri, N., Fallon, M. B., Noureddin, M., Arab, J. P., & Wijarnpreecha, K. (2024) · Journal of Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 29

One-Carbon Metabolism in Liver Health and Disease

Mato, J. M., Martínez-Chantar, M. L., Noureddin, M., & Lu, S. C. (2017) · Liver Pathophysiology

Folate and B Vitamins ResearchMetabolism and Genetic Disorders

Cited by 12

Improvement in nonalcoholic fatty liver disease through bariatric surgery

Truong, E., & Noureddin, M. (2022) · Clinical Liver Disease

Bariatric Surgery and OutcomesLiver Disease Diagnosis and Treatment

Cited by 10

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes

Cited by 9

Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials

Francque, S. M., Noureddin, M., & Krag, A. (2024) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 9

From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New

Alabdul Razzak, I., Noureddin, M., & Trivedi, H. (2024) · Journal of Clinical Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 5

WED-263 A machine learning approach to identify patient features associated with metabolic dysfunction-associated steatohepatitis from the United Kingdom biobank

Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., Karamchandani, U., Romero, J., Henstock, P., Emir, B., & Sanyal, A. J. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare

Cited by 1

THU-242 Comparison ofmachine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database

Noureddin, M., Rubinsztain, J., Taub, K., Chang, D. Y., Harrison, S. A., & Alkhouri, N. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1

SAT-214 Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)

Schattenberg, J. M., Anstee, Q. M., Harrison, S. A., Noureddin, M., Taub, R., Labriola, D., Priel, J., & Padmanabhan, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 1

THU-233 External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease

Alkhouri, N., Rubinsztain, J., Taub, K., Harrison, S. A., Chang, D. Y., & Noureddin, M. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1